BRAF and cutaneous melanoma: These include drugs targeting the mitogen activated protein-kinase (MAPK) pathway, namely, BRAF and MEK inhibitors, in patients with BRAF mutant melanoma (i.e., approximately 50% of patients with cutaneous melanoma) [2,3].